Bjermer 2016.
Study characteristics | ||
Methods | Parallel, double‐blind RCT with a 16‐week treatment phase | |
Participants | 315 participants (42 male) with moderate‐severe asthma, with airway reversibility, blood eosinophilia, ACQ score of at least 1.5, and taking ICS
|
|
Interventions | IV infusion of reslizumab 0.3 mg/kg, reslizumab 3.0 mg/kg, or placebo once every 4 weeks (total of 4 doses) | |
Outcomes | Primary outcome
Secondary outcomes
|
|
Notes | 68 locations across 13 countries Funded by Teva Branded Pharmaceutical Products R&D, Inc |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Not stated, no clarification available from study authors |
Allocation concealment (selection bias) | Unclear risk | Not stated, no clarification available from study authors |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | Double‐blind |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not stated, no clarification available from study authors |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Slightly more withdrawals in placebo group (20/105, 19%) than treatment arms (12‐17%) |
Selective reporting (reporting bias) | Low risk | All outcomes reported |